Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF CB-010, A NEXT-GENERATION CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR-T CELL THERAPY, IN PATIENTS WITH REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS (GALLOP)
A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF CB-010, A NEXT-GENERATION CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR-T CELL THERAPY, IN PATIENTS WITH REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS (GALLOP) Chatham, W., Fiorenza, S., Weinmann-Menke, J., Sanchez-Pernaute, O., Lafayette, R., Askanase, A., Gerber, M., Alexander, L., Mao, P., Garner, E., Kwong, G., Fowler, T., Kufeldt, H., Kerfs, B., Brown, A., Holland, C., Mcwilliams, K., Shah, G., Garrett, A., Bryan, M., Chu, L., Alambra, E., Skoble, J., Kochy, T., Nesheiwat, T., Zudaire, E., Portella, S. J RHEUMATOL PUBL CO. 2025: 147-148View details for Web of Science ID 001573431600217